Key Points
- Director Stephen Denelsky purchased 10,000 shares at $4.87 on March 17 for $48,700, raising his stake to 21,000 shares (a 90.91% increase), according to an SEC filing.
- Harvard Bioscience shares traded at $4.92 (up 0.7%) with a market cap of about $22 million, trading below its 50- and 200-day moving averages (~$5.59/$5.66) and showing a negative P/E of -0.38.
- Analysts are mixed with a consensus rating of "Hold" and an average price target of $6.00; notable notes include Benchmark cutting its target from $20 to $6 and Weiss Ratings maintaining a "sell (d-)."
Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) Director William Snider bought 8,475 shares of the business's stock in a transaction dated Tuesday, March 17th. The shares were bought at an average cost of $4.85 per share, for a total transaction of $41,103.75. Following the completion of the transaction, the director directly owned 32,000 shares of the company's stock, valued at $155,200. This trade represents a 36.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
William Snider also recently made the following trade(s):
- On Monday, March 16th, William Snider bought 12,525 shares of Harvard Bioscience stock. The shares were bought at an average cost of $4.99 per share, with a total value of $62,499.75.
Harvard Bioscience Trading Up 4.3%
Shares of NASDAQ:HBIO traded up $0.21 during midday trading on Thursday, reaching $5.09. The company had a trading volume of 19,711 shares, compared to its average volume of 46,492. The company has a fifty day simple moving average of $5.59 and a two-hundred day simple moving average of $5.66. The firm has a market cap of $22.75 million, a price-to-earnings ratio of -0.40 and a beta of 1.51. Harvard Bioscience, Inc. has a 1-year low of $2.81 and a 1-year high of $9.50. The company has a debt-to-equity ratio of 2.61, a quick ratio of 0.41 and a current ratio of 2.20.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on HBIO. New Street Research set a $6.00 target price on shares of Harvard Bioscience in a research report on Friday, March 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Benchmark decreased their price objective on shares of Harvard Bioscience from $20.00 to $6.00 and set a "speculative buy" rating for the company in a research note on Friday, March 13th. Finally, Zacks Research upgraded shares of Harvard Bioscience to a "hold" rating in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $6.00.
Read Our Latest Stock Analysis on HBIO
Institutional Trading of Harvard Bioscience
Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Harvard Bioscience in the fourth quarter worth approximately $40,000. Goldman Sachs Group Inc. grew its position in Harvard Bioscience by 291.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier's stock valued at $33,000 after purchasing an additional 37,057 shares in the last quarter. Jane Street Group LLC increased its stake in Harvard Bioscience by 491.9% in the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier's stock valued at $31,000 after buying an additional 58,785 shares during the period. XTX Topco Ltd acquired a new position in Harvard Bioscience in the 4th quarter valued at approximately $26,000. Finally, Meros Investment Management LP lifted its position in Harvard Bioscience by 32.6% in the 4th quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier's stock worth $814,000 after buying an additional 299,369 shares in the last quarter. 80.87% of the stock is owned by hedge funds and other institutional investors.
Harvard Bioscience Company Profile
(
Get Free Report)
Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company's product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.
Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
